Regular paperRole of oxidative stress in atherosclerosis☆
Section snippets
Enzyme systems in the regulation of vascular oxidases
The NADPH oxidases have emerged as very important sources of ROS in vascular cells.4 An important aspect of this enzyme system is that it is regulated by a variety of pathophysiologic stimuli relevant to atherosclerosis, including angiotensin II, physical forces, and inflammatory cytokines. Recent work from Griendling et al4 has elucidated the signaling mechanism involved in angiotensin II activation of the NADPH oxidases.7 As shown schematically in Figure 3, it has been demonstrated at the
Physical forces in the regulation of vascular oxidases
In the 1980s, Ku et al12 demonstrated that oscillations of flow occur at sites in the circulation where atherosclerosis develops. In a model of the carotid bulb that allowed examination of flow profiles, these investigators demonstrated that there is reversal of flow with oscillations during systole. Such disturbances of flow profiles occur not only in the carotid bulb, but also in the abdominal aorta and the proximal coronary arteries, areas clearly predisposed to atherosclerosis.13 It has
Uncoupling of NOS
The NOSs, and in particular the endothelial isoform of NOS (eNOS), have emerged as important sources of superoxide in the last few years. These enzymes use 5,6,7,8-tetrahydrobiopterin (BH4) as a cofactor for transfer of electrons from a heme group within the oxygenase domain to l-arginine to form l-citrulline and NO. If either BH4 or l-arginine is absent, the electrons from heme reduce oxygen to form superoxide.15 In mice with deoxycorticosterone acetate salt hypertension, we have recently
Conclusions
Research from a number of laboratories has supported a role of ROS in the genesis of atherosclerosis, both in experimental animals and in humans. It is of interest that recent large trials have failed to show a benefit of antioxidant vitamins on cardiovascular outcome. We believe that future studies, should they be performed, should use antioxidants that are much more potent than the vitamins used in prior studies. Further, treatment of oxidative stress could be aided greatly by plasma or
References (21)
- et al.
Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals
Am J Hypertens
(2002) - et al.
Endothelial dysfunction in cardiovascular diseasesthe role of oxidant stress
Circ Res
(2000) - et al.
Hypercholesterolemia increases endothelial superoxide anion production
J Clin Invest
(1993) - et al.
Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits
Proc Natl Acad Sci U S A
(1996) - et al.
NADPH oxidaserole in cardiovascular biology and disease
Circ Res
(2000) - et al.
Mitochondrial integrity and function in atherogenesis
Circulation
(2002) - et al.
Endothelial regulation of vasomotion in apoE-deficient miceimplications for interactions between peroxynitrite and tetrahydrobiopterin
Circulation
(2001) - et al.
Angiotensin II stimulation of NAD(P)H oxidase activityupstream mediators
Circ Res
(2002) - et al.
Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells
Hypertension
(1999) - et al.
Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone
J Clin Invest
(1996)
Cited by (1102)
Antioxidant nanozymes as next-generation therapeutics to free radical-mediated inflammatory diseases: A comprehensive review
2024, International Journal of Biological MacromoleculesAmelioration of experimental hyperlipidemia in rats by Portulaca oleracea Linn from Kashmir Himalaya
2024, Journal of King Saud University - ScienceEffects of two-month treatment with a mixture of natural activators of autophagy on oxidative stress and arterial stiffness in patients with essential hypertension: A pilot study
2023, Nutrition, Metabolism and Cardiovascular Diseases
- ☆
This work was supported by a grant from atherogenics, inc.